Breast Cancer Survivor Educational Intervention

Purpose

The goal of this study is to test a 6-week virtual education program among Black breast cancer survivors. The virtual program includes sessions on physical activity, goal setting, nutrition, sleep, stress, and social connections.

Conditions

  • Breast Cancer
  • Breast Neoplasms
  • Breast Carcinoma
  • Breast Cancer Female

Eligibility

Eligible Ages
Over 22 Years
Eligible Genders
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Female - Self-identified Black or African American race - Age 22-79 - Diagnosis of Stage I, II, or III invasive breast cancer - Completed active treatment at least 6 months ago, but within the past five years - Speaks English

Exclusion Criteria

  • Undergoing active treatment (i.e., surgery, chemotherapy, radiation) - Undergoing evaluation for suspected recurrence

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Supportive Care
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Breast Cancer Survivor Education Program
Participants will complete study procedures as outlined: - 6 weekly sessions of a modified version of the PAVING the Path to Wellness education program.
  • Behavioral: Breast Cancer Survivor Education Program
    Weekly sessions via Zoom platform with study staff.

Recruiting Locations

Massachusetts General Hospital Cancer Center
Boston, Massachusetts 02215
Contact:
Erica Warner, MPH, ScD
617-724-9516
ewarner@mgh.harvard.edu

More Details

Status
Recruiting
Sponsor
Massachusetts General Hospital

Study Contact

Erica Warner, MPH, ScD
617-724-9516
ewarner@mgh.harvard.edu

Detailed Description

This six-week feasibility study will evaluate a virtual support and education program among up to 15 Black female breast cancer survivors. Participants will be asked to attend a 90 minute group session once a week for 6 weeks and complete surveys pre and post intervention surveys to ascertain study endpoints. This study is supported by funding from Pfizer and in-kind support from the American Cancer Society, Inc.